ArticlePloS one2022
Evaluation and prevention and control measures of urban public transport exposure risk under the influence of COVID-19-Taking Wuhan as an example.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
- Article
- Are the epidemic prevention facilities effective? How cities should choose epidemic prevention facilities: Taking Wuhan as an example.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince December 2019, COVID-19 began to spread throughout the world for nearly two years. During the epidemic, the travel intensity of most urban residents has dropped significantly, and they can only complete inflexible travel such as "home to designated hospital" and "home to supermarket" and some special commuting trips. While ensuring basic travel of residents under major public health emergency, there is also a problem of high risk of infection caused by exposure of the population to the public transport network. For the discipline of urban transport, how to use planning methods to promote public health and reduce the potential spread of diseases has become a common problem faced by the government, academia and industry.
methodBased on the mobility perspective of travel agents, the spatial analysis methods such as topological model of bus network structure, centrality model of public transport network and nuclear density analysis are used to obtain the exposure risk and spatial distribution characteristics of public transport from two aspects of bus stops and epidemic sites.
resultsThe overall spatial exposure risk of Wuhan city presents an obvious "multi center circle" structure at the level of bus stops. The high and relatively high risk stops are mainly transport hubs, shopping malls and other sites, accounting for 35.63%. The medium and low-risk stops are mainly the villages and communities outside the core areas of each administrative region, accounting for 64.37%. On the other hand, at the scale of epidemic sites, the coverage covers 4018 bus stops in Wuhan, accounting for 36.5% of all bus stops, and 169 bus lines, accounting for 39.9% of all routes. High risk epidemic sites are mainly concentrated in the core areas within the jurisdiction of Wuhan City, and in the direction of urban outer circle diffusion, they are mainly distributed in the low and medium risk epidemic sites. According to the difference of the risk level of public transport exposure, the hierarchical public transport control measures are formulated. DISCUSSION: This paper proposes differentiated prevention and control countermeasures according to the difference of risk levels, and provides theoretical basis and decision-making reference for urban traffic management departments in emergency management and formulation of prevention and control countermeasures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.